Insmed reports second-quarter 2023 financial results and provides business update

-- arikayce® (amikacin liposome inhalation suspension) total revenue of $77.2 million for the second quarter of 2023 reflects highest quarter of sales since launch and 18% growth compared to the second quarter of 2022 --  -- company raises full-year 2023 guidance range for global arikayce revenues to $295 million to $305 million --  -- topline data from post-marketing arise study of arikayce expected in september of 2023 --  -- blended blinded dose titration data for tpip in ph-ild and pah expected in second half of 2023 --  -- topline data from the phase 3 aspen trial of brensocatib in adult patients with bronchiectasis remains on track to read out in the second quarter of 2024 --  bridgewater, n.j. , aug. 3, 2023 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended june 30, 2023 and provided a business update.
INSM Ratings Summary
INSM Quant Ranking